Bilirubin: A potential biomarker and therapeutic target for diabetic nephropathy

Diabetes

Volumn 63, Issue 8, 2014, Pages 2613-2616

  Hull, Travis D ^a,b   Agarwal, Anupam ^a,c  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LOSARTAN; MALE; TETRAZOLES;

EID: 84905026674     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0691     Document Type: Note

References (27)

1. American Diabetes Association. Executive summary: Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl. 1):S4-S10
2. Riphagen IJ, Deetman PE, Bakker SJL, et al. Bilirubin and progression of nephropathy in type 2 diabetes: a post-hoc analysis of RENAAL with independent replication in IDNT. Diabetes 2014; 63:2845-2853
3. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969; 244:6388-6394
4. Vítek L., Jirsa M, Brodanová M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002; 160: 449-456
5. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005; 288:F778-F784
6. Fujii M, Inoguchi T, Sasaki S., et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010; 78:905-919
7. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000; 1: 328-335
8. Rodby RA, Rohde RD, Clarke W.R., et al.; For the Collaborative Study Group. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000; 15:487-497
9. Bosma PJ, Chowdhury JR, Bakker C, et al The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171-1175
10. *28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008; 198:1-11
11. Balla J, Vercellotti GM, Jeney V, et al Heme, heme oxygenase and ferritin in vascular endothelial cell injury. Mol Nutr Food Res 2005; 49:1030-1043
12. Gibbs PE, Tudor C, Maines MD Biliverdin reductase: more than a namesake - the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front Pharmacol 2012; 3:31
13. Chen YH, Chau LY, Chen J.W., Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008; 31:1615-1620
14. Chen YH, Kuo KL, Hung S.C., Hsu CC, Chen YH, Tarng DC. Length Polymorphism in Heme Oxygenase-1 and Risk of CKD among Patients with Coronary Artery Disease. J Am Soc Nephrol. 24 April 2014 [Epub ahead of print]
15. Kang SJ, Lee C, Kruzliak P. Effects of serum bilirubin on atherosclerotic processes. Ann Med 2014; 46:138-147
16. Hull TD, Agarwal A, George JF The mononuclear phagocyte system in homeostasis and disease: a role for heme oxygenase-1. Antioxid Redox Signal 2014; 20:1770-1788
17. Stocker R, Yamamoto Y, McDonagh A.F., Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235:1043-1046
18. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107:1058-1070
19. -(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J 2010; 432:9-19
20. Rodella L, Lamon BD, Rezzani R, et al Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. Free Radic Biol Med 2006; 40:2198-2205
21. Pflueger A, Croatt AJ, Peterson T.E., et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 2005; 288:F552-F558
22. Maruhashi T, Soga J, Fujimura N., et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation 2012; 126:598-603
23. Nath KA, d'Uscio LV, Juncos JP, et al An analysis of the DOCA-salt model of hypertension in HO-1-/- mice and the Gunn rat. Am J Physiol Heart Circ Physiol 2007; 293:H333-H342
24. Peyton KJ, Shebib AR, Azam M.A., Liu XM, Tulis DA, Durante W. Bilirubin inhibits neointima formation and vascular smooth muscle cell proliferation and migration. Front Pharmacol 2012; 3:48
25. Kimm H, Yun JE, Jo J, Jee SH Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009; 40:3422-3427
26. Lee JP, Kim do H, Yang SH, et al Serum bilirubin affects graft outcomes through UDP-glucuronosyltransferase sequence variation in kidney transplantation. PLoS ONE 2014; 9:e93633
27. Cheriyath P, Gorrepati VS, Peters I, et al High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999-2006. J Clin Med Res 2010; 2:201-206